Application Nr Approved Date Route Status External Links
ANDA206318 None Transdermal None Google , Wikipedia , PubMed , DailyMed , Raw OpenFDA , ECHA , ToxNet , JECFA , FAO , 21 CFR

Indications and Purposes

1 Indications And Usage Rivastigmine Transdermal System Is An Acetylcholinesterase Inhibitor Indicated For Treatment Of: Mild, Moderate, And Severe Dementia Of The Alzheimer's Type (Ad) ( 1.1 ) Mild-To-Moderate Dementia Associated With Parkinson's Disease (Pd) ( 1.2 ) 1.1 Alzheimer’s Disease Rivastigmine Transdermal System Is Indicated For The Treatment Of Dementia Of The Alzheimer's Type (Ad). Efficacy Has Been Demonstrated In Patients With Mild, Moderate, And Severe Alzheimer's Disease. 1.2 Parkinson’s Disease Dementia Rivastigmine Transdermal System Is Indicated For The Treatment Of Mild-To-Moderate Dementia Associated With Parkinson's Disease (Pdd).

All Formulated Excipients (0 Total)

None

Active Ingredients ( 1 Total)

Name Structure ZINC ID(s)
1. Rivastigmine RIVASTIGMINE ZINC4413

Comments